Collecting blood samples to study biomarkers in pancreatic cancer
Official title: Protocol to Permit Collection of Circulating Biomarkers in Pancreatic Cancer
Run by Abramson Cancer Center at Penn Medicine · NCT05743049 · Data updated 2026-11-12
This study is collecting blood samples from patients with pancreatic cancer to see if certain markers in the blood can help improve diagnosis and treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | February 27, 2023 |
| Main results expected | June 30, 2027 |
| Study ends | January 15, 2028 |
| Registry record updated | April 7, 2026 |
| Trial ID | NCT05743049 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with a known or presumed diagnosis of pancreatic adenocarcinoma who are patients at the University of Pennsylvania.
✕Probably not a fit
Patients with significant psychiatric, social, or medical conditions that could interfere with their ability to participate or provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study involves collecting blood samples from patients diagnosed with pancreatic adenocarcinoma to evaluate circulating biomarkers. The goal is to analyze these biomarkers to better understand their role in pancreatic cancer. Participants must be patients at the University of Pennsylvania and provide informed consent. The study aims to gather valuable data that could lead to improved diagnostic and therapeutic strategies for pancreatic cancer.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of pancreatic cancer and lead to better diagnostic tools and treatment options for patients.
How similar studies have gone: While this study focuses on biomarker collection, similar studies have shown promise in understanding cancer biology and improving patient outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma * The subject must be a patient of the University of Pennsylvania * The subject must be able to provide informed consent * The subject must be 18 years of age or older Exclusion Criteria: . Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.
Where it's running
-
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Mark O'Hara, MD — Abramson Cancer Center, University of Pennsylvania
- Study coordinator: Liudmila Mazaleuskaya, PhD
- Email: mazali@pennmedicine.upenn.edu
- Phone: 267-455-9141
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liquid biopsy biomarkers to detect and monitor pancreatic cancer
Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.
-
INSPIRE: Putting patient-reported info into multidisciplinary tumor boards
This study tests whether adding electronic patient-reported outcomes to tumor board discussions can help guide treatment decisions for women with breast, gynecologic, pancreatic cancers and related cancers.
-
MRI scan for detecting pancreatic cancer in people at high risk
This study tests a dedicated pancreas MRI (MRP) tool to see if it helps find pancreatic cancer earlier in people with a strong family or genetic risk.
-
Cutting down ultra-processed foods for people at high cancer risk
This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.
-
Carbon nanoparticle‑loaded iron for advanced solid tumors
This test uses direct injections of a carbon nanoparticle‑loaded iron medicine (CNSI‑Fe) to see if it can shrink tumors in adults with advanced solid cancers who have no effective standard treatment options.
-
Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids
This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.